When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
GNMSF - Genmab's ofatumumab flunks late-stage NHL study
Genmab A/S Dkk
Genmab A/S (OTCPK:GNMSF)(OTCPK:GMXAY) announces that a Phase 3 clinical trial evaluating Arzerra (ofatumumab) plus bendamustine in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) who have not responded to Roche's Rituxan (rituximab) failed to demonstrate a statistically valid treatment effect compared to bendamustine alone.
More news on: Genmab A/S, Genmab A/S ADR, Novartis AG, Healthcare stocks news, Stocks on the move,